flâneur

OCTO

noetik.ai · 2,493 words · saved by 1 readers

After a decade of deep learning, AI is ready to make an impact on drug development. Large-scale models like AlphaFold, Evo, and ESM3 can now predict the structure of biomolecules with near experimental accuracy and design selective therapies against them. While this addresses one hurdle in drug development, most drugs still fail not because of their structure, but because they target the wrong proteins or are tested in the wrong patients. This is a fundamentally different problem and to date there are no models that tell us which targets to drug or in which patients to drug them. ‍ This is because complex diseases, like cancer, rarely boil down to a single gene or protein. Instead, different genetic, cellular, and tissue-level processes drive disease across different patient populations, making it difficult to predict how a drug will affect a given person. For some classes of drugs, like immunotherapies which work by activating immune response, the pathways are poorly understood and th

OCTO - Noetik Company Platform Partnerships Insights Careers NOETIK TECHNICAL REPORT 1 World Models as Simulators of Patient Biology July 16, 2024 After a decade of deep learning, AI is ready to make an impact on drug development. Large-scale models like AlphaFold , Evo , and ESM3 can now predict the structure of biomolecules with near experimental accuracy and design selective therapies against them. While this addresses one hurdle in drug development, most drugs still fail not because of their structure, but because they target the wrong proteins or are tested in the wrong patients. This is

saved by

related reading